Skip to main
CBIO

GlycoMimetics Inc (CBIO) Stock Forecast & Price Target

GlycoMimetics Inc (CBIO) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Crescent Biopharma Inc. exhibits a positive outlook driven by the successful HARMONi-A OS trial results, which demonstrate that CR-001 can deliver significant survival advantages in non-small cell lung cancer (NSCLC) patient populations where existing treatments like Keytruda are not standard of care. The company’s proprietary bispecific antibody, designed to enhance clinical efficacy and safety, aligns with emerging data that suggest bispecific therapies may extend survival beyond established PD-1-dominated indications. Furthermore, Crescent’s partnership agreements regarding drug candidates similar to CR-001, particularly in terms of lucrative financial terms, signal a strong market interest that may further bolster the company’s financial position and growth potential.

Bears say

Crescent Biopharma Inc faces significant risks that may negatively impact its stock outlook, primarily stemming from the potential for adverse events related to its lead product, CR-001, and competitive challenges in the PD-1/L1 x VEGF drug landscape. Additionally, the company's ability to advance CR-001 through clinical trials remains uncertain, posing a risk of stagnation in product development. Further complicating the situation is the possibility that CR-001 may demonstrate an inferior efficacy profile compared to existing therapies, contributing to a valuation gap that could undermine investor confidence.

GlycoMimetics Inc (CBIO) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GlycoMimetics Inc (CBIO) Forecast

Analysts have given GlycoMimetics Inc (CBIO) a Strong Buy based on their latest research and market trends.

According to 6 analysts, GlycoMimetics Inc (CBIO) has a Strong Buy consensus rating as of Feb 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GlycoMimetics Inc (CBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.